Royalty Report: Drugs, Disease, Bacterial Infection – Collection: 203561

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Bacterial Infection
  • Therapeutic
  • Antibiotic
  • Drug Discovery
  • Assay
  • Diagnostic
  • Pharmaceuticals
  • Cancer
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203561

License Grant
Licensor shall assign to Licensee Licensors entire right, title and interest in and to the Compound Patents pursuant to a patent assignment agreement executed on the same date as this Agreement and any Oxazolidinone Compound synthesized, discovered and/or developed by Licensor prior to the Effective Date.

For the research licenses, Licensor grants during the Research Term a worldwide, exclusive, with reserved rights to Licensor, a license, under the Licensor Know-how and Patents as necessary for Licensee to conduct its obligations and tasks under the Research Plan.

For the commercialization license, Licensor grants during the Term of this Agreement a worldwide, exclusive license under the Licensors Know-how and Patents to use, make, have made, market, distribute, promote, offer for sale, sell, export and import Product, including the right to grant sublicenses to Affiliates and Sublicensees.

License Property
The Compound means any composition of matter,  excluding any Oxazolidinone Compound, whether patented or not, that Licensee synthesized prior to the Effective Date, but excluding any Included Licensee Compound, or any ester, salt, hydrate, solvate or prodrug of the foregoing Compounds.

The oxazolidinone class of antibiotics is a relatively recent addition to the antimicrobial world and have been found to be especially useful in treating infections caused by Gram-positive bacteria.

The patents are for Method For Solid Phase Synthesis of Alcohol Derivatives and Resulting Compositions;  and Oxazolidinone Combinatorial Libraries, Compositions and Methods of Preparation.
This application discloses methods for the solid phase synthesis of oxazolidinones; oxazolidinone combinatorial libraries and methods for their synthesis; pharmaceutical compositions comprising bioactive oxazolidinone compounds, including those adapted for oral, topical or parenteral use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect compounds with activity for treatment of disease states such as inflammation, infection, hypertension, CNS disorders and cardiovascular disorders.

TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
This application discloses combinatorial libraries comprising oxazolidinones; methods of preparation of the libraries; biologically active oxazolidinone compositions including compositions for use for the treatment of bacterial infections; and methods of screening combinatorial libraries to detect bioactive compounds useful for treatment of disease states such as inflammation, infection, hypertension, central nervous system disorders and cardiovascular disorders.

TITLE OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION
Biologically active oxazolidinones, libraries and pharmaceutical compositions, and methods of preparation are disclosed, wherein the biologically active oxazolidinones may be used in pharmaceutical applications including use as sedatives, anticonvulsants, muscle relaxants, anti-Parkinson agents, analgesics, antiinflammatories, local anesthetics, muscle contractants, antibiotic, antiviral, antiretroviral, antimalarials, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics and chemotherapy agents, as well as for treatment of cardiovascular diseases, central nervous system diseases, cancer, metabolic disorders, infections and dermatological diseases as well as other biological disorders and infections.

Field of Use
The field means antibacterial use in humans.

IPSCIO Record ID: 266746

License Grant
Licensor grants the Licensee of Ireland the exclusive, even as to Licensor license, under the Licensor Technology and the Licensor Joint Technology Rights, to sell, offer for sale, have sold, import, export and Commercialize Licensed Products in the Territory.

Licensor grants the nonexclusive license, under the Licensor Technology, to practice and use the Licensor Technology and the Licensed Products anywhere in the world for the sole purpose of engaging in those research and development activities that Licensee is expressly required or permitted to perform pursuant to this Agreement.

Licensor grants a nonexclusive license, under the Licensor Technology, to make, have made, manufacture and have manufactured anywhere in the world Licensed Products for sale in the Territory.

For the Trademark License,  Licensor grants an exclusive license under its entire right, title and interest in and to the Licensor Marks to use and display the Licensor Marks in connection with the Commercialization of Licensed Products within the Territory.

License Property
Licensor is developing a proprietary compound known under the generic name of daptomycin, and in particular a form of daptomycin which is administered by intravenous injection.

Daptomycin shall mean the molecule identified as the daptomycin molecule and all acids, salts and esters of such daptomycin molecule.

Daptomycin IV Product shall mean any pharmaceutical composition containing Daptomycin in all current and future formulations, but only if such pharmaceutical composition is formulated for delivery via Injection.  

Additional Daptomycin Product shall mean any pharmaceutical composition containing Daptomycin other than a Daptomycin N Product.

The mark is Cidecin or Cubicen. CUBICIN® daptomycin for injection, an intravenous, or I.V., antibiotic

Field of Use
The Licensee possesses capabilities in the promotion and marketing of anti-infective pharmaceutical products throughout Europe and certain other countries.  

Daptomycin is an antibiotic used to treat bacterial infections of the skin and underlying tissues.  Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms.

IPSCIO Record ID: 239020

License Grant
This agreement is between the Licensor, the Licensee and the Institute Licensee which is a division of the Licensee.

For the Research Program, Licensor agrees to conduct the Research Program in collaboration with the Licensee Institute partner with a goal of discovering, identifying and synthesizing Licensed Compounds for Development by Institute Licensee into one or more Products for commercialization by Licensee, an Affiliate or Sublicensee.

During the Exclusive Screening Period, the Institute Licensee shall have the exclusive right to screen Macrolides provided by Licensor for Antibiotic Activity.

During the Non-exclusive screening period, the Institute Licensee and its Affiliates shall have the non-exclusive right to screen the Macrolides, for any biological activity, in any biological test system for any therapeutic indication.

During the Non-exclusive screening period, the Institute Licensee shall have a non-exclusive right to screen the Aromatic Polyketides for any biological activity in any biological test system for any therapeutic indication.

For the Research Licenses to the Institute Licensee, Licensor grants the Institute Licensee a non-exclusive license, with no right to grant sublicenses, under Licensor Patent Rights  and Know-how to make and use methods and materials to carry, out the Research Program during the Research Term.

For the Screening Licenses, Licensor grants to the Institute Licensee the non-transferable licenses, with the right to grant sublicenses to the Institute Licensee Affiliates, under the Licensor Patent Rights and Know-how to conduct screening, an exclusive, worldwide license during the exclusive screening period to use the Macrolides, to conduct screening for Antibiotic Activity;

– a non-exclusive, worldwide license during the non-exclusive screening period (a) to use the Macrolides to conduct screening for Antibiotic Activity; (b) to use the Aromatic Polyketides to conduct screening for any activity; and

– a non-exclusive, worldwide license during the Exclusive Screening Period and Non-exclusive screening period to use the Macrolides to conduct screening for activities other than Antibiotic Activity, excluding any right to screen the Macrolides for Motilide or Anti-inflammatory Activity.

For the Development and Commercialization License Grant, Licensor grants to Licensee a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor patent rights and know-how, to make, use and develop Licensed Compounds, and, to make, have made, use, import, offer for sale, sell and have Sold Products.

License Property
The Licensed Compound shall mean a particular Macrolide or Aromatic Polyketide, as the case may be, with respect to which the Institute Licensee has provided a Designated Notice and acquired an exclusive license. For purposes of this Agreement, each Close Structure Analog of any such Licensed Compound shall also be deemed to be a Licensed Compound.

Macrolides shall mean 14-membered macrolactones, such as erythromycin, their 3-ketolide congeners, 12-membered macrolactones, 15-membered and 16-membered macrolactones, and other macrolactones or ketolide congeners agreed by the Joint Committee, in each case, obtained by expression of genes from, polyketide, synthase gone clusters including, but not limited to, the erythromycin, rapamycin, tylosin, candicidin, picromycin, or oleandomycin] polyketide, synthase gene clusters, in each case, which are actually utilized in connection with the Research Program that exist in Licensors proprietary compound library as of the effective date; or are synthesized or acquired by or on behalf of Licensor or Licensee in connection with the Research Program.

Motilide Activity shall mean motilin receptor agonist or antagonist activity.

Product shall mean any pharmaceutical product containing a Licensed Compound or a Derivative thereof which is selected for Development and/or marketing by Licensee or its Affiliates or Subllicensees.

Field of Use
Field shall mean the treatment of bacterial infections for all human and animal pharmaceutical applications.

IPSCIO Record ID: 305615

License Grant
Licensor hereby agrees to conduct the research program in consultation with Licensee with a goal of discovering, identifying and synthesizing collaboration compounds for development by Licensee into one or more licensed products for commercialization by Licensee. The research program shall be conducted in accordance with the overall research plan.
License Property
Licensed Product shall mean any collaboration compound selected for development and marketing by Licensee.

Collaboration Compound shall mean any composition of matter in the field (or in the case of pro-drugs, an active metabolite of which), other than a natural product or synthetic or semi-synthetic derivative thereof, that (i) was discovered, identified, synthesized or acquired by or on behalf of Licensor as of the effective date, (ii) is discovered, identified, synthesized or acquired by or on behalf of Licensor during the research term and for six (6) months thereafter, or (iii) is contained within a chemical genus as defined in any issued claim of any unexpired patent in the patent rights, or in a claim of a pending application for such a patent which is being prosecuted in good faith, and as to which one member of such chemical genus is defined in (i) or (ii) above. For purposes of determining whether a given composition is a collaboration compound, it is understood that a composition which is discovered, identified, synthesized or acquired during the research term or within six (6) months thereafter (the Applicable Date) shall be included as a collaboration compound notwithstanding whether the composition was identified as being active in the field after the Applicable Date.

Development shall mean all work involved in Phases O, I, II, and III for a Licensed product in any country or territory.

U.S. Serial No. 08/377,583 – Screening Procedure for Penicillin-binding protein inhibitors.

Research Program shall mean all research and development performed, directed or acquired by Licensor in the course of performing the research plan during the research term.

Licensor is a biopharmaceutical company founded to discover, develop and commercialize novel antibiotics for the treatment of serious bacterial infections. The Companys discovery and development programs address the growing problem of bacterial drug resistance through two principal themes (i) Targeted Antibiotics, which focuses on developing novel antibiotics and antibiotic potentiators, and (ii) Targeted Genomics, which utilizes bacterial genetics to discover new classes of antibiotics and other novel treatments for bacterial disease.

Field of Use
The collaboration agreement is to discover and develop novel beta-lactam antibiotics, antibiotic potentiators and inhibitors of bacterial signal transduction targeted at problematic Gram-positive bacteria, including staphylococci and enterococci.

The targeted Antibiotics programs seek to rapidly develop clinically useful antibiotics tailored to treat specific bacterial infections, as well as antibiotic potentiators, which will overcome resistance pathways and restore usefulness to existing antibiotics that have been rendered ineffective. The specific problematic bacteria being addressed (staphylococci, enterococci, Pseudomonas aeruginosa and Streptococcus pneumoniae) are responsible for 44% of the approximately two million hospital-acquired infections occurring annually in the United States.

Field shall mean the field of
(i) cephalosporin antibiotics active against Gram-positive bacteria with MICs (minimum inhibitory concentrations) of ~ 32,/g/ml against staphylococci, enterococci and pneumococci, as determined by NCCLS recommended methods;
(ii) novel compounds and compositions which react with penicillin binding protein, including but not limited to PBP2a, with an ICso ! 50,/g/ml in a standard penicillin binding protein assay, provided that research activities are initiated in this ponion of the field prior to start of the nineteenth (19th) month of the research term;
(iii) non-antibacterial beta-lactam or glycopeptide antibiotic potentiators, including specifically, but not limited to, compounds that exen their e~ect primarily by inhibition of methicillin and vancomycin resistance mechanisms, and potentiators that exen their effect primarily by inhibition of histidyl-aspartyl two component switch regulatory system in bacteria, which non-antibacterial beta-lactam or glycopeptide antibiotic potentialOr exhibits MICs (minimum inhibitory concentrations) alone, against staphylococci, enterococci and pneumococci of ~32ys/ml. as determined by NCCLS recommended methods, but not including (a) quinolone potentiators or (b) potentiators or antibacterials which work primarily by inhibition of bacterial efflux pumps, or (c) beta-lactamase inhibitors ;
(iv) compounds or compositions discovered through the use of genes, gene products and Licensor screens in the Agr (accessory gene regulator) pathway of Staphylococcus aureus, or functionally homologous genes in other Gram-positive organisms, in either instance including histidyl-aspartyl two component switch regulatory systems in the Agr pathway;
(v) antibiotics which act through the histidyl-aspartyl two component switch regulatory system discovered using Licensor know-how developed in performance of the research program during the research term, or within six (6) months thereafter (i.e., new hits and leads and new discovery screens for histidine protein kinase inhibitors developed during the course of the research program), with MICs (minimum inhibitory concentrations) of~16/lg/ml against Gram-positive and/or Gram-negative organisms, as determined by NCCLS recommended methods, all for use in treating bacterial infections for all human and animal pharmaceutical applications.

Licensee has been engaged in research efforts focused on the development of new antibacterials and has certain research, development and commercialization capabilities in the field.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 266736

License Grant
Licensor, a non-profit hospital, grants to Licensee to the extent of the Licensed Territory an exclusive license under the patent rights to make, have made, use, sell and have sold, and import licensed products in the Licensed Field, with the right to sub license.

Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.

License Property
Licensor owns US Patent application for Methods of Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth, and, US Patent entitled Methods of Diagnosing or Treating Irritable Bowel Syndrome and Other Disorders Caused by Small Intestinal Bacterial Overgrowth.

Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.

Field of Use
Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.

IPSCIO Record ID: 239024

License Grant
The Licensor of Spain grants to an exclusive, even as to Licensor, license under the Patent Assets and the Licensor Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, promote, market, commercialize, distribute and sell Product in the Territory, and insofar as necessary for the purposes of exercising such rights, to develop, make, have made, use, import, offer for sale, commercialize, distribute and sell Compound.
License Property
The compound is UR-12746 Sodium Salt, meaning UR-12746 (including UR-12715) and UR-12746(S), and any derivative, homolog or analog of any of the foregoing or any isomer, salt, hydrate, solvate, amide, ester, metabolite, or prodrug of any of the foregoing, and any pharmaceutical composition containing any of the foregoing in any pharmaceutically acceptable form.

Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.

Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.

Field of Use
Dersalazine is a compound in early clinical development to treat Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn's disease.

IPSCIO Record ID: 227289

License Grant
The parties agree to collaborate with each other relating to the discovery and optimization of compounds for use in the Field with respect to certain biological targets within the Field.

Screening License – Licensor hereby grants to Licensee a nonexclusive, worldwide, royalty-free license (without the right to sublicense) under the Licensor Patent Rights and other rights in the Licensor Technology to screen Licensor Compounds delivered under the collaboration against Anti-Infective Targets and Anti-Fungal Targets in the Field, but only during the Screening Phase.

Develop and Commercialize License – Licensor hereby grants to Licensee and its Affiliates the following licenses

         (i)      an exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to conduct development of Licensed Compounds in the Field, including the right to develop Analog Compounds based on Licensed Compounds.;
         (ii)     an exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to make, have made, use, have used, sell, and import Licensed Compounds and certain identified Analog Compounds, as described below, in the Field; and
         (iii)    a non-exclusive, worldwide license (with the right to sublicense) under the Licensor Patent Rights and other rights in Licensor Technology to use chemical synthesis methods within the Licensor Patent Rights and Licensor Technology to make and have made Royalty-Bearing Products.

License Property
Licensor Compound means a chemical compound owned or controlled by Licensor provided by Licensor to Licensee pursuant to this Agreement as part of a screening library, including without limitation the compounds provided in the Compass Array Library and Mapping Array Libraries.

Licensed Compound Se means a set of one or more Licensed Compounds from the same Mapping Array Library that have biological activity for the same Target, as well as any Licensor Analog Compounds of such Licensed Compounds that are synthesized by a party in the course of optimizing those Licensed Compounds.

Patent Rights means any United States and foreign patent application and any divisional, continuation, or continuation-in-part of such patent application (to the extent the claims are directed to subject matter specifically described therein), as well as any patent issued thereon and any reissue or reexamination of such patent, and any foreign counterparts to such patents and patent applications.

Field of Use
Field means all applications in the life sciences relating to human therapeutic products for the treatment, prophylaxis or diagnosis of infectious diseases caused by bacterial organisms.

IPSCIO Record ID: 352727

License Grant
Licensor of Korea grants a sole and exclusive license under the Licensor Patents, Licensor Know-How, Licensor Licensed Patents and Know-how to use, import, package, sell and offer for sale Products within the Field in the Territory, as well as the exclusive right to use the Trademarks in the Territory in conjunction with the use or sale of Products.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
Licensor is the owner of all right, title and interest in certain patents and know-how relating to Gemifloxacin, an antibiotic.

Active Pharmaceutical Ingredient or API means Gemifloxacin in active bulk.

Licensor Licensed Patents include but is not limited to
– Dimethane-sulfonate salt of certain pyrrolidinium compounds and the process for the
prearation thereof and the process for the preparation of gemifloxacin free base or salts using AM 19.
– The process for direct salt  and hydrate formation of gemifloxacin mesylate sesquihydrate using a water-miscible cosolvent and water.
– The process for gemifloxacin free base or salts using an agueous solvent.
– Combination Therapy (gemifloxacin and B-lactam).
– Combination Therapy (gemifloxacin and carbapenem).

The trademarks are FACTIVE, FACTIVE DEV, FACPAC3DAY, FACPAC7 and dev., and FAST. ACTIVE. FACTIVE.

DNA nanobinder compounds are compounds that exhibit significant antibacterial activity, have at least one heteroaromatic carboxamide unit, are first synthesized in an internal GS research program (including research programs funded by the United States government but excluding collaborative research programs with a non-governmental third party) and typically but not necessarily bind to the minor groove of double-stranded DNA with an affinity in the nanomolar range.

Field of Use
FACTIVE (gemifloxacin mesylate) is used to treat a variety of bacterial infections. This medication belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections.

IPSCIO Record ID: 935

License Grant
The original agreement assigned to Licensee all right, title and interest to a Compound and patents thereon known as Kevetrin.

After executing the Prior Agreement and filing for and obtaining Kevetrin Patents, Licensor, two individuals, and Licensee learned that a joint inventor of Kevetrin was inadvertently omitted from the Kevetrin Patents.  The Licnesor then acquired the entire interest of the joint inventor in Kevetrin and the Kevetrin Patents and, consistent with the Prior Agreement, hereby assigns to Cellceutix all of the joint inventor’s right, title and interest in and to Kevetrin and the Kevetrin Patents.

License Property
Kevetrin means the substance identified by the chemical structure set forth in the U.S. Patent No. 8,338,454, all hydrates, salts and esters of that substance, all enantiomers of the substance, all mixtures of the foregoing, all substances developed using any of the foregoing as starting material, as intermediates or as a model or template, and all substances claimed in any Kevetrin Patent.

Kevetrin Patents means all patents and patent applications anywhere in the world that disclose and claim a Compound or its therapeutic uses, including U.S. Patent No. 8,338,454 (“’454 Patent”), all worldwide patent applications that rely for priority on the ‘454 Patent or on any of the applications from which the ‘454 Patent directly or indirectly issued (including U.S. Patent Application No. 13/685,879, filed November 27, 2012), all worldwide patents issuing from any of the foregoing  applications, and all reexaminations, reissues or extensions of any of the foregoing patents.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.